SD PHARMA
Sources: the KBO register on 21-11-2026; the National Bank, 2025 annual accounts filed on 31-07-2026; the Belgian Official Gazette, latest deed of 06-12-2023.
Grounds
the facts the verdict rests on, each with its source- SD PHARMA made a profit in every financial year since 2008.Annual accounts 2008 to 2025 page 2
- Equity stands at €1.0m, or 86.6% of the balance sheet total of €1.2m. The solvency of 86.6% is higher than at 85% of the 10,288 companies filing micro accounts in financial services (NACE 64) in 2025.Annual accounts 2025 page 2
- The 2025 accounts came in on the last day of the term; the 2024 accounts 12 days late.National Bank, filing of 31-07-2026 page 5
Representation
The sole director, , represents SD PHARMA alone.
Articles of association, Belgian Official Gazette of 06-12-2023, deed 23447433
Ownership
The accounts in the micro format list no shareholders. is a shareholder. According to the deed of 03-03-2014, holds all the shares.
Deed of 03-03-2014, deed 14054272
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Gross margin and net resultin €m
Equity and debtsin €m
Cashin €m
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Gross margin | €143,713 | €145,134 | €131,850 | €129,775 | €127,292 | |
| Operating result | €140,811 | €142,829 | €129,490 | €127,164 | €124,817 | |
| Net result | €95,548 | €90,720 | €90,068 | €89,023 | €89,819 | |
| Balance sheet at the closing date | ||||||
| Equity | €686,668 | €777,388 | €867,456 | €956,479 | €1.0m | |
| Debts | €398,633 | €311,740 | €245,287 | €199,105 | €161,321 | |
| Debts due after more than one year | €230,819 | €167,834 | €131,386 | €94,459 | €57,045 | |
| Debts due within one year | €167,814 | €143,906 | €112,701 | €104,647 | €104,276 | |
| Cash | €770 | €5,877 | €26,089 | €37,364 | €22,904 | |
| Balance sheet total | €1.1m | €1.1m | €1.1m | €1.2m | €1.2m | |
| Ratios | ||||||
| Solvency | 63.3% | 71.4% | 78.0% | 82.8% | 86.6% | |
| Liquidity | 0.13 | 0.19 | 0.44 | 0.68 | 1.15 | |
Source: Annual accounts 2025, micro format, filed on 31-07-2026 (2026-00365837); Annual accounts 2024, micro format, filed on 12-08-2025 (2025-00371206); Annual accounts 2021 to 2023, filed from 21-07-2022 to 29-07-2024 (2022-20211714, 2023-00324295, 2024-00294254).
Debts fell by €37,785 in 2025.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
SD PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €129,775 to €127,292.
Board, signature and ownership
Position on 21-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The sole director, , represents SD PHARMA alone.
Articles of association, Belgian Official Gazette of 06-12-2023, deed 23447433
Board
one director in officeOwnership and group
Shareholders
The accounts in the micro format list no shareholders. is a shareholder. According to the deed of 03-03-2014, holds all the shares.
Deed of 03-03-2014, deed 14054272
Board changes
changes role from manager to director. General meeting of 30-11-2023.
Gazette, deed 23447433Holdings
SD PHARMA has 1 direct subsidiary (own 2025 accounts).
| Country | Company | Equity | Result | |
|---|---|---|---|---|
| Belgium 1 | ||||
| BE | €383,912 | result €16,674 | ||
Source: List of holdings in its own 2025 accounts. Every holding stands with its own latest accounts.
Events and comparison
The latest events, newest first
Annual accounts 2025 filed. On the deadline day.
NBB filingEquity above €1m. With a profit in every financial year since 2008, equity grows to €1.0m.
FinancialAnnual accounts 2024 filed, 12 days late.
NBB filingAnnual accounts 2023 filed, 2 days before the deadline.
NBB filingAnnual accounts 2022 filed, 10 days late.
NBB filingAnnual accounts 2021 filed, 10 days before the deadline.
NBB filingHighest result from 2008 to 2025. The net result of €95,548 is the highest of those years.
FinancialAnnual accounts 2020 filed, 1 day before the deadline.
NBB filingAnnual accounts 2019 filed, 31 days before the deadline.
NBB filingEquity above €500,000. With a profit in every financial year since 2008, equity grows to €554,439.
FinancialAnnual accounts 2018 filed. On the deadline day.
NBB filingAnnual accounts 2017 filed, 9 days late.
NBB filingAnnual accounts 2016 filed, 25 days before the deadline.
NBB filingRegistered office moved from Sint-Truiden to Alken. The registered office moved from Stapelstraat 20, 3800 Sint-Truiden to Wetzerstraat 6 A, 3570 Alken. General meeting of 01-01-2017.
Gazette, deed 17031315The return on assets of SD PHARMA, 7.4%, is higher than at 45% of the 10,139 companies filing micro accounts in financial services (NACE 64) in 2025.
Other findings
Peppol
Reachable for e-invoices since 24-11-2025, under 0208:0895359290.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 21-11-2026 | KBO 0895.359.290 |
| National Bank of Belgium | Annual accounts 2025, micro format | 31-07-2026 | 2026-00365837 |
| National Bank of Belgium | Annual accounts 2024, micro format | 12-08-2025 | 2025-00371206 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 21-07-2022 to 29-07-2024 | 2022-20211714, 2023-00324295, 2024-00294254 |
| Belgian Official Gazette | Articles of association with the signing rule | 06-12-2023 | deed 23447433 |
| Belgian Official Gazette | All shares held by one shareholder | 03-03-2014 | deed 14054272 |
| Peppol Directory | Registration for e-invoices | 24-11-2025 | 0208:0895359290 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 20-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 20-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
The scores and ratios are Checked's own calculations, not a credit decision.